Our 3D cell culture platforms described in detail, including the 3D tumor growth assay (3D TGA) using PDX-derived cells.

Oncology drug development has an overly high attrition rate for novel agents in late-phase clinical trials, which needs to be improved to enhance the efficiency and cost-effectiveness of developing new therapies. Precision profiling using Patient-Derived Xenografts (PDX), the most predictive...

• Syngeneic models, showcasing our ever expanding syngeneic collection, FACS analysis, and checkpoint inhibitor benchmarking
• MuScreen™ CrownBio’s large-scale, staggered screening platform to fast-track the in vivo screening of immunotherapy compounds
• MuPrime™ - allografts of spontaneous murine...

• Evaluating Cell Line Derived Xenograft and Patient-Derived Xenograft (PDX) models in humanized mice, including immune memory response
• MiXeno™ models featuring transient human immunity in mice, providing a simple alternative to the full stem cell reconstitution approach
• HuGEMM™ and HuCELL™, our...

Our PDX collection key features are summarized in our HuPrime^® FactSheet

Fusion oncogenic events are important targets for oncology research, potentially providing ‘druggable’ targets for subsets of cancer patients. We currently provide FactSheets on:

CrownBio also provides details on our comprehensive Non-GLP Toxicology and Safety Pharmacology assessments in NHPs and rodents

CrownBio provides a comprehensive In Vivo Immunotherapy Translational Technology Platform, and our FactSheets bring you detailed information across a range of our immuno- oncology services.